Reviews/Psoriasis Psoriatic Arthritis/IL-17 inhibitors: axial psoriatic arthritis versus axial spondyloarthritis response
Psa Axl · PSA-AXL-02 · v2
This claim says people with axial psoriatic arthritis respond less well to biologic drugs than people with ankylosing spondylitis, and that this holds across several different drug types. The evidence collected here points the other way: the two studies that look specifically at axial psoriatic arthritis found response almost identical to ankylosing spondylitis [3], [7], and several real-world registries found the two conditions do about equally well [5], [6], [8]. Where one study did see a gap in patient-reported outcomes, it was in a mixed psoriatic arthritis group and the gap disappeared once other factors were accounted for [1]. A second problem is that every study here uses the same single drug, secukinumab, so the claim's assertion about multiple drug classes simply cannot be checked with this evidence. The panel therefore found the claim contradicted for the one drug class observed and untestable for the rest.
The two papers that isolate axial psoriatic arthritis both report response comparable to ankylosing spondylitis: 61.5% versus 62.2% at six months with no significant difference (p=0.91) [3], and axial-PsA ASAS20 response of 63% and 66% versus 31% placebo, described as broadly comparable to AS trials [7]. Real-world registries reinforce parity: remission/inactive-disease rates of 15.5/25.4/30.5% in PsA versus 18/23.7/28.6% in axSpA with no significant difference [6], comparable disease-activity improvements across AS and PsA [5], and comparable outcomes with retention of 74.9% (PsA) versus 78.9% (AS) [8]. A crude patient-reported gap favouring axSpA in a mixed PsA cohort became similar after adjustment for confounders [1]. No paper reports axial PsA responding worse than AS on a like-for-like basis. The contested point: The only directional hint toward the claim is the crude, unadjusted patient-reported difference in [1], and it is in general (not axial) PsA and disappears once confounders are accounted for. The rest of the corpus divides only on how directly it addresses the axial phenotype ([3], [7] specifically versus general PsA cohorts elsewhere), not on the direction of effect.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two papers that isolate axial PsA ([3], [7]) both report parity with AS, so the claim's asserted lower-response direction fails on its own best on-target evidence.
The entire corpus is a single molecule (secukinumab, IL-17A). The claim's 'across multiple drug classes' scope is wholly untestable — no TNF, IL-23, or JAK data exist here.
Where it remains uncertain. Every study uses a single molecule, secukinumab, so the claim's 'across multiple drug classes' scope cannot be tested here, and most comparisons use general rather than axial PsA cohorts [1], [2], [4], [5], [6], [8].
Aleatory
The direct axial-PsA comparison rests on modest counts (44/72 axial PsA vs 28/45 axSpA in [3]), so chance variation around the point estimates is non-trivial.
Epistemic
Every paper is secukinumab (IL-17A); nothing in the corpus observes TNF, IL-23, or JAK inhibitors, so the multi-class claim is unobserved rather than tested.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only signal in the claim's direction is crude, in general PsA, and nullified after adjustment for confounders
“Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar.”
Panel auditInternal validity: medium · scope of inference: Daily-practice axSpA vs PsA patients on secukinumab, patient-reported remission and retention over 24 months.Key limitations: PsA/axSpA overall, not axial PsA vs AS · single drug class (secukinumab) · crude vs adjusted results diverge · no numbers in abstract
Direct axial-PsA-vs-axSpA comparison shows near-identical effectiveness, contradicting a lower axial-PsA response
“44/72 patients with axial PsA (61.5%) and 28/45 patients with axSpA (62.2%; p=0.91)”
Panel auditInternal validity: medium · scope of inference: Argentine real-world axial PsA vs axSpA patients on secukinumab, effectiveness and survival.Key limitations: axSpA comparator, not AS specifically · single drug class (secukinumab) · modest sample size · real-world, unadjusted
Independent registry supports cross-condition parity
“Secukinumab is effective and safe in patients with AS and PsA in a real-life setting, with comparable disease-activity improvements across conditions.”
Panel auditInternal validity: medium · scope of inference: Real-life multicenter AS vs PsA patients on secukinumab, disease-activity improvement at 6 and 12 months.Key limitations: PsA overall, not axial PsA · single drug class (secukinumab) · no numbers or statistical test reported
4-year retention was approximately 50% in both groups, so the abstract shows no lower performance in PsA, contrary to the claim's assertion of lower rates.
Panel auditInternal validity: medium · scope of inference: European real-world axSpA vs PsA patients on secukinumab, 24-48 month retention.Key limitations: PsA/axSpA overall, not axial PsA vs AS · retention not response rate · single drug class (secukinumab)
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus consistently shows comparable, not lower, response in axial PsA versus AS within the one drug class it covers, and cannot support the multi-class generalisation the claim asserts.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No non-IL-17 drug classes. The claim spans multiple drug classes but the corpus is entirely secukinumab, so the multi-class comparison is untestable here. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Head-to-head or matched-cohort studies of TNF, IL-23, and JAK inhibitors comparing axial PsA and AS response on the same endpoints.
Open question: Do TNF, IL-23, or JAK inhibitors show comparable or lower response in axial PsA versus ankylosing spondylitis? Why it is still open: The corpus contains only secukinumab, so no non-IL-17 class is observed at all.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19